BRIEF published on 09/16/2026 at 08:05, 14 days 8 hours ago TME Pharma NV's strategy and financial commitment Biotechnology Partnerships Financial Strategy TME Pharma NOX-A12
BRIEF published on 09/16/2026 at 08:05, 14 days 8 hours ago Stratégie et engagement financier de TME Pharma N.V. Biotechnologie Stratégie Financière Partenariats TME Pharma NOX-A12
PRESS RELEASE published on 09/16/2026 at 08:00, 14 days 8 hours ago TME PHARMA CEO MESSAGE TME Pharma CEO message emphasizes strategic approach, financial discipline, and long-term value creation for shareholders. Updates on NOX-A12, cost-reduction strategy, and future plans CEO Message Financial Discipline TME Pharma Strategic Approach NOX-A12
PRESS RELEASE published on 09/16/2026 at 08:00, 14 days 8 hours ago MESSAGE DU CEO DE TME PHARMA TME Pharma publie une lettre aux actionnaires du CEO. Détails sur la stratégie financière, les partenariats pour le NOX-A12, la gestion du capital et les activités futures Stratégie Financière Partenariats CEO TME Pharma NOX-A12
BRIEF published on 08/24/2026 at 08:10, 1 month 6 days ago TME Pharma Advances Toward Strategic Partnerships for Cancer Therapy Glioblastoma NOX-A12 Licensing Partnerships Biotech Market Trends CEO Share Transaction
BRIEF published on 08/24/2026 at 08:10, 1 month 6 days ago TME Pharma progresse vers des partenariats stratégiques pour la thérapie du cancer Glioblastome NOX-A12 Partenariats De Licence Tendances Du Marché Des Biotechnologies Transaction D'actions Du PDG
PRESS RELEASE published on 08/24/2026 at 08:05, 1 month 6 days ago TME Pharma provides update on its activities TME Pharma provides update on its activities including final evaluation phase with potential partners for NOX-A12, with estimated peak sales potential of $1 billion, strategic decision framework, and scientific validation Clinical-stage Biotechnology License Agreement TME Pharma NOX-A12 Brain Cancer
PRESS RELEASE published on 08/24/2026 at 08:05, 1 month 6 days ago TME Pharma fait le point sur ses activités TME Pharma fait le point sur ses activités et les négociations pour un accord de licence pour NOX-A12, médicament phare pour le cancer du cerveau. Analyse stratégique en cours Biotechnologie Accord De Licence TME Pharma NOX-A12 Cancer Du Cerveau
BRIEF published on 10/30/2025 at 21:05, 10 months 30 days ago TME Pharma's Semi-Annual Report and Financial Restructuring Financial Results Biotechnology CEO Appointment Bond Issuance TME Pharma
BRIEF published on 10/30/2025 at 21:05, 10 months 30 days ago Rapport semestriel et restructuration financière de TME Pharma Résultats Financiers Biotechnologie Emission D'obligations Nomination Du PDG TME Pharma
Published on 09/30/2026 at 15:50, 25 minutes ago Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans
Published on 09/30/2026 at 14:37, 1 hour 38 minutes ago NuRAN Leverages Starlink Backhaul to Drive Higher Revenue Per Rural Site
Published on 09/30/2026 at 14:31, 1 hour 44 minutes ago First Breach Expands Ammunition Manufacturing Operations to Seven Days a Week
Published on 09/30/2026 at 14:07, 2 hours 8 minutes ago Worksport COR Energy System Now Available Through Amazon
Published on 09/30/2026 at 13:30, 2 hours 45 minutes ago Nextech3D.ai Engages MZ Group to Lead Strategic Investor Relations Program
Published on 09/30/2026 at 16:00, 15 minutes ago Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Published on 09/30/2026 at 15:41, 34 minutes ago Branicks Group AG 2026 Half-Year Report: Steady Operational Progress, Key Structural Changes Implemented
Published on 09/30/2026 at 15:10, 1 hour 5 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 09/30/2026 at 15:09, 1 hour 5 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 09/30/2026 at 12:14, 4 hours 1 minute ago Mise à disposition du rapport financier semestriel au 30 juin 2026
Published on 09/30/2026 at 12:00, 4 hours 15 minutes ago Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 09/30/2026 at 12:00, 4 hours 15 minutes ago Capital increase through exercise of subscription rights
Published on 09/30/2026 at 08:45, 7 hours 30 minutes ago Air Liquide invests over 170 million euros to support a semiconductor leader expanding manufacturing capabilities in Japan
Published on 09/30/2026 at 08:45, 7 hours 30 minutes ago Air Liquide investit plus de 170 millions d’euros pour accompagner un leader des semi-conducteurs dans le développement de ses capacités de production au Japon
